Compare OC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | GKOS |
|---|---|---|
| Founded | 1938 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.9B |
| IPO Year | 2006 | 2015 |
| Metric | OC | GKOS |
|---|---|---|
| Price | $144.41 | $181.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $145.27 | $126.92 |
| AVG Volume (30 Days) | ★ 776.9K | 761.2K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | $3.72 | $27.43 |
| P/E Ratio | $95.79 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $97.53 | $73.16 |
| 52 Week High | $159.91 | $191.62 |
| Indicator | OC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 60.38 |
| Support Level | $135.25 | $175.04 |
| Resistance Level | $145.52 | $184.00 |
| Average True Range (ATR) | 3.87 | 6.01 |
| MACD | -1.51 | -1.59 |
| Stochastic Oscillator | 8.02 | 39.63 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.